Compare · ABMD vs WST
ABMD vs WST
Side-by-side comparison of ABIOMED Inc. (ABMD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABMD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.05B, about 1.7x ABMD ($12.61B).
- WST has hit the wire 7 times in the past 4 weeks while ABMD has been quiet.
- WST has more recent analyst coverage (16 ratings vs 9 for ABMD).
- Company
- ABIOMED Inc.
- West Pharmaceutical Services Inc.
- Price
- $381.11+0.07%
- $312.48-1.09%
- Market cap
- $12.61B
- $22.05B
- 1M return
- -
- +3.92%
- 1Y return
- -
- +48.29%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 9
- 16
ABIOMED Inc.
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest ABMD
- Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical
- SEC Form SC 13G/A filed by ABIOMED Inc. (Amendment)
- SEC Form 15-12G filed by ABIOMED Inc.
- SEC Form SC 13G filed by ABIOMED Inc.
- SEC Form 4: Sutter Martin P returned 123,370 shares to the company, closing all direct ownership in the company
- SEC Form 4: Puhy Dorothy E returned 14,590 shares to the company, closing all direct ownership in the company
- SEC Form 4: Trapp Todd A returned 14,166 shares to the company, closing all direct ownership in the company
- SEC Form 4: Plano Matthew T. returned 8,406 units of Common Stock $.01 par value to the company, closing all direct ownership in the company
- SEC Form 4: Minogue Michael R returned 410,632 units of Common Stock $.01 par value to the company, closing all direct ownership in the company
- SEC Form 4: Greenfield Andrew J returned 23,484 shares to the company, closing all direct ownership in the company
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)